The purpose of this study is to evaluate whether vepoloxamer can provide a blood chemical marker and functional benefit to damaged heart muscle cells. This will be evaluated by measurement of blood-based laboratory markers, exercise tolerance, and echocardiograms. In addition, the safety and blood levels of vepoloxamer in subjects with chronic heart failure will be evaluated.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
10
Research Center
Detroit, Michigan, United States
Research Center
Tupelo, Mississippi, United States
Research Center
Cardiff, New South Wales, Australia
Research Center
Melbourne, Victoria, Australia
Number of subjects with a change in cardiac biomarkers ultra-high sensitive troponin I and NT-proBNP
Time frame: Study Day 1 through Study Day 30
Number of subjects with a change in Six Minute Walk test
Time frame: Study Day 1 to Study Day 30
Number of subjects with a change in Borg dyspnea index
Time frame: Study Day 1 to Study Day 30
Number of subjects with a change in Minnesota Living with Heart Failure Questionnaire®
Time frame: Study Day 1 to Study Day 30
Number of subjects with a change in left ventricular end diastolic volume index
Time frame: Study Day 1 to Study Day 30
Number of subjects with treatment-related adverse events as assessed by CTCAE v 4.03
Time frame: Study Day 1 to Study Day 30
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.